Emerson Collective Cancer Research Fund
Opens May 5 2021 12:00 AM (PDT)
Deadline Jun 16 2021 11:59 PM (PDT)
Description

Please Note: By clicking “Apply” you acknowledge and agree to the following:

  1. Any information you may learn about Emerson Collective during the application process should remain strictly confidential. This includes information about Emerson Collective and its affiliates, employees, and agents; current and prospective grantees, portfolio companies and other partners; research, strategies and other business activities; and any other non-public information that Emerson Collective wishes to maintain as confidential.
  2. You are not permitted to use Emerson Collective’s name or logo in any external communications (such as emails, social media, etc.) without prior written consent.
  3. Emerson Collective’s acceptance of a proposal neither commits Emerson Collective to award a contract to any supplier nor limits Emerson Collective’s rights in any way, and (by way of example and not limitation) Emerson Collective may do any or all of the following: 
    1. Accept or reject any proposals, in part or in whole;
    2. Request further clarification on any specific response, omission or claim made in a response to the RFP; 
    3. Further evaluate one or more proposals via additional interviews/presentations, or other additional criteria; and 
    4. Further negotiate the terms submitted in a proposal, including price, prior to the final award.


Who We Are

Emerson Collective deploys a wide range of tools—from impact investing to philanthropy to advocacy—in pursuit of a more equal and just America.  We focus on creating systemic change in education, immigration, climate, and cancer research and treatment.

Advances in cancer research—including the advent of genetic sequencing, immunology, and improvements in disease detection—have combined to make this a pivotal moment of potential progress in cancer biology research and treatment.  Thanks to these developments, we see new tangible steps that can be taken to potentially reduce the burden of cancer in the lives of patients, their families, and caregivers.

Emerson Health partners with leading, cutting-edge researchers and innovative entrepreneurs to help transform groundbreaking scientific discoveries into potentially groundbreaking treatments for patients with significant, unmet needs.

We place patients at the center of our efforts by giving them tools that empower them to play a more integral role in their own treatment—including access to the latest research and clinical trials, and ownership of their own medical data.

We work across the entire drug development pipeline, from the lab to the clinic, and across all types of cancer and modalities of treatment.

By encouraging collaboration and innovation across the entire cancer research ecosystem, we aim to accelerate the technology, treatments, and standard of care that have the power to improve the health and lives of cancer patients.


What We Support

The Emerson Collective Cancer Research Fund is requesting individual or team proposals for research projects related to the following topic areas:

•  Engineering allogeneic cells with new properties to:

  1. prevent their recognition by the host immune system;
  2. promote their persistence in the host;
  3. defeat suppressive mechanisms of the tumor microenvironment;
  4. synergize with host innate and adaptive immune systems; and/or,
  5. allow gating or other regulation of their functions temporally or geographically to improve potency or reduce toxicity.  

•  Validating new target antigens for cell therapy in cancer

•  Targeted intracellular gene or protein delivery mechanisms

•  Enabling early cancer detection


Who is Eligible to Apply

This RFA is open to all faculty and trainees sponsored by faculty undertaking research relevant to cancer at eligible research institutions.  Awards range from one to two years, and must include both direct and indirect costs in a proposed budget.  Additional questions regarding eligibility should be emailed to healthgrants@emersoncollective.com


How We Evaluate

Emerson Collective will evaluate applications on the following positive criteria:

•  The audacity and innovation of the research proposal

•  The potential of the proposed research to affect multiple cancer types

•  The potential to translate research into further experiments, and clinical trials

•  The applicant’s lack of resources to pursue the proposed research

•  Compliance with a two-year maximum timeframe for research

Please note: The applicant’s prior experimental track record will not be the principal determining factor in evaluation.  This fund does not support incremental research.  Emerson Collective evaluates the applicant’s current and pending support.  Duplication of proposed science is grounds for Emerson Collective to return the proposal without review.

Apply

Emerson Collective Cancer Research Fund


Please Note: By clicking “Apply” you acknowledge and agree to the following:

  1. Any information you may learn about Emerson Collective during the application process should remain strictly confidential. This includes information about Emerson Collective and its affiliates, employees, and agents; current and prospective grantees, portfolio companies and other partners; research, strategies and other business activities; and any other non-public information that Emerson Collective wishes to maintain as confidential.
  2. You are not permitted to use Emerson Collective’s name or logo in any external communications (such as emails, social media, etc.) without prior written consent.
  3. Emerson Collective’s acceptance of a proposal neither commits Emerson Collective to award a contract to any supplier nor limits Emerson Collective’s rights in any way, and (by way of example and not limitation) Emerson Collective may do any or all of the following: 
    1. Accept or reject any proposals, in part or in whole;
    2. Request further clarification on any specific response, omission or claim made in a response to the RFP; 
    3. Further evaluate one or more proposals via additional interviews/presentations, or other additional criteria; and 
    4. Further negotiate the terms submitted in a proposal, including price, prior to the final award.


Who We Are

Emerson Collective deploys a wide range of tools—from impact investing to philanthropy to advocacy—in pursuit of a more equal and just America.  We focus on creating systemic change in education, immigration, climate, and cancer research and treatment.

Advances in cancer research—including the advent of genetic sequencing, immunology, and improvements in disease detection—have combined to make this a pivotal moment of potential progress in cancer biology research and treatment.  Thanks to these developments, we see new tangible steps that can be taken to potentially reduce the burden of cancer in the lives of patients, their families, and caregivers.

Emerson Health partners with leading, cutting-edge researchers and innovative entrepreneurs to help transform groundbreaking scientific discoveries into potentially groundbreaking treatments for patients with significant, unmet needs.

We place patients at the center of our efforts by giving them tools that empower them to play a more integral role in their own treatment—including access to the latest research and clinical trials, and ownership of their own medical data.

We work across the entire drug development pipeline, from the lab to the clinic, and across all types of cancer and modalities of treatment.

By encouraging collaboration and innovation across the entire cancer research ecosystem, we aim to accelerate the technology, treatments, and standard of care that have the power to improve the health and lives of cancer patients.


What We Support

The Emerson Collective Cancer Research Fund is requesting individual or team proposals for research projects related to the following topic areas:

•  Engineering allogeneic cells with new properties to:

  1. prevent their recognition by the host immune system;
  2. promote their persistence in the host;
  3. defeat suppressive mechanisms of the tumor microenvironment;
  4. synergize with host innate and adaptive immune systems; and/or,
  5. allow gating or other regulation of their functions temporally or geographically to improve potency or reduce toxicity.  

•  Validating new target antigens for cell therapy in cancer

•  Targeted intracellular gene or protein delivery mechanisms

•  Enabling early cancer detection


Who is Eligible to Apply

This RFA is open to all faculty and trainees sponsored by faculty undertaking research relevant to cancer at eligible research institutions.  Awards range from one to two years, and must include both direct and indirect costs in a proposed budget.  Additional questions regarding eligibility should be emailed to healthgrants@emersoncollective.com


How We Evaluate

Emerson Collective will evaluate applications on the following positive criteria:

•  The audacity and innovation of the research proposal

•  The potential of the proposed research to affect multiple cancer types

•  The potential to translate research into further experiments, and clinical trials

•  The applicant’s lack of resources to pursue the proposed research

•  Compliance with a two-year maximum timeframe for research

Please note: The applicant’s prior experimental track record will not be the principal determining factor in evaluation.  This fund does not support incremental research.  Emerson Collective evaluates the applicant’s current and pending support.  Duplication of proposed science is grounds for Emerson Collective to return the proposal without review.

Apply
Opens
May 5 2021 12:00 AM (PDT)
Deadline
Jun 16 2021 11:59 PM (PDT)